MarketCap
Facebook
X
Telegram
Myomo Revenue | MYO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Myomo
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.9 M | 32.6 M | 19.2 M | 1 B | 13.9 M | 7.58 M | 3.84 M | 2.44 M | 1.56 M | 1.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1 B | 1.1 M | 112 M |
Quarterly Revenue Myomo
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.7 M | 10.1 M | 10.1 M | 9.65 M | 9.83 M | - | 9.21 M | 7.52 M | 3.75 M | - | 5.08 M | 5.96 M | 3.45 M | - | 3.97 M | 3.68 M | 3.87 M | - | 4.38 M | 3.1 M | 2.34 M | - | 1.93 M | 859 K | 1.01 M | - | 607 K | 880 K | 830 K | - | 609 K | 632 K | 313 K | - | 489 K | 307 K | 216 K | - | 184 K | 254 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 184 K | 3.77 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Inari Medical
NARI
|
494 M | - | - | $ 4.23 B |  USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 5.88 | 2.46 % | $ 795 M | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 103.03 | 1.02 % | $ 179 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
366 M | - | - | $ 3.31 B | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Align Technology
ALGN
|
4.03 B | $ 152.58 | 1.17 % | $ 11.1 B | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 2.93 | 0.86 % | $ 120 M | USA |
 |
Alphatec Holdings
ATEC
|
764 M | $ 10.8 | 2.03 % | $ 1.62 B | USA |
 |
AxoGen
AXGN
|
225 M | $ 43.52 | 3.23 % | $ 2 B | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | USA |
 |
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M |  Israel |
 |
Nemaura Medical
NMRD
|
77 K | - | -17.8 % | $ 2.74 M |  Britain |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Sientra
SIEN
|
25.1 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
177 M | - | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
82 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
730 M | - | - | $ 12.3 B | USA |
 |
ThermoGenesis Holdings
THMO
|
9.44 M | - | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
2.13 M | - | 3.55 % | $ 7.96 M | USA |
 |
Viveve Medical
VIVE
|
6.43 M | - | -15.35 % | $ 1.71 M | USA |
 |
ViewRay
VRAY
|
102 M | - | 1.54 % | $ 468 M | USA |
 |
Titan Medical
TMDI
|
20.1 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Natus Medical Incorporated
NTUS
|
473 M | - | 1.94 % | $ 1.05 B | USA |
 |
Acutus Medical
AFIB
|
20.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | USA |
 |
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | USA |
 |
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | USA |
 |
SmileDirectClub
SDC
|
471 M | - | -53.45 % | $ 9.71 M | USA |
 |
Bruker Corporation
BRKR
|
3.44 B | $ 52.35 | 0.19 % | $ 7.95 B | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 44.87 | 4.45 % | $ 66.4 B | USA |
 |
Accuray Incorporated
ARAY
|
402 M | $ 0.25 | 0.44 % | $ 30.7 M | USA |
 |
Bio-Rad Laboratories
BIO
|
2.58 B | $ 369.1 | 0.09 % | $ 10.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
400 M | $ 8.3 | 3.49 % | $ 605 M | Israel |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 13.52 | 0.18 % | $ 383 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 46.61 | 0.63 % | $ 1.45 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 5.91 | 0.63 % | $ 368 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 16.32 | 2.58 % | $ 585 M | USA |
 |
Electromed
ELMD
|
73.8 M | $ 26.39 | 0.4 % | $ 218 M | USA |
 |
Establishment Labs Holdings
ESTA
|
211 M | $ 71.54 | 0.85 % | $ 2.12 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 85.31 | 1.11 % | $ 49.9 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 75.29 | 1.42 % | $ 10.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
6.02 M | $ 2.21 | 0.23 % | $ 48.7 M | USA |
 |
Inogen
INGN
|
349 M | $ 5.27 | 0.09 % | $ 140 M | USA |
 |
InMode Ltd.
INMD
|
370 M | $ 14.87 | 0.2 % | $ 961 M | Israel |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.66 | 0.74 % | $ 11.2 M | USA |